The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review

Detalhes bibliográficos
Autor(a) principal: Sousa, Jemilly Ferreira de
Data de Publicação: 2022
Outros Autores: Lima, Edilson Soares, Carvalho, Mônica Aparecida Miranda, Soares, Pedro Henrique Coêlho, Muniz, Raquel Santos, Reis, Renandro de Carvalho
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/27282
Resumo: Objective: The research focuses on addressing the importance of SAH as a potential risk factor in patients affected by COVID-19. Methods: The methodology adopted in the present study was based on a systematic literature review, in its qualitative sphere, the result of studies based on 10 scientific articles, once listed for the formation of this study. Results: The total number of people with SAH in the present sample is 5,234 with a mean age of 60 years. The most used drugs were Calcium Channel Antagonists, Angiotensin Receptor Beta Blockers (ARB), Angiotensin Converting Enzyme Inhibitors (ACEI) and Alpha Blockers. In this meander, the results showed that the use of (ACEI) and Angiotensin Receptor Blockers (ARB), compared to non-ACEI/ARB, do not worsen COVID-19. Current evidence suggests that SARIs should be continued in the case of patients infected with the virus. Some studies have reported that SAH patients are at greater risk of having a more serious condition if they test positive for the new strain of coronavirus. Conclusion: The present research concluded that hypertensive patients with COVID-19 are at greater risk of worsening the disease than non-hypertensive patients. These findings reveal that the worsening of the condition of hypertensive patients and those with COVID-19 is due to the renin-angiotensin-aldosterone system (RAAS), which ends up favoring the binding of the virus to the body of these individuals.
id UNIFEI_d02bc6b6149416fbd32c7b04940a6a43
oai_identifier_str oai:ojs.pkp.sfu.ca:article/27282
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling The effects of COVID-19 on patients with systemic arterial hypertension: a systematic reviewLos efectos del COVID-19 en pacientes con hipertensión arterial sistémica: una revisión sistemáticaOs efeitos da COVID-19 em pacientes com hipertensão arterial sistêmica: uma revisão sistemáticaCovid-19Systemic Arterial HypertensionHypertensive.Covid-19Hipertensión Arterial SistémicaHipertensos.Covid-19Hipertensão Arterial SistêmicaHipertensos.Objective: The research focuses on addressing the importance of SAH as a potential risk factor in patients affected by COVID-19. Methods: The methodology adopted in the present study was based on a systematic literature review, in its qualitative sphere, the result of studies based on 10 scientific articles, once listed for the formation of this study. Results: The total number of people with SAH in the present sample is 5,234 with a mean age of 60 years. The most used drugs were Calcium Channel Antagonists, Angiotensin Receptor Beta Blockers (ARB), Angiotensin Converting Enzyme Inhibitors (ACEI) and Alpha Blockers. In this meander, the results showed that the use of (ACEI) and Angiotensin Receptor Blockers (ARB), compared to non-ACEI/ARB, do not worsen COVID-19. Current evidence suggests that SARIs should be continued in the case of patients infected with the virus. Some studies have reported that SAH patients are at greater risk of having a more serious condition if they test positive for the new strain of coronavirus. Conclusion: The present research concluded that hypertensive patients with COVID-19 are at greater risk of worsening the disease than non-hypertensive patients. These findings reveal that the worsening of the condition of hypertensive patients and those with COVID-19 is due to the renin-angiotensin-aldosterone system (RAAS), which ends up favoring the binding of the virus to the body of these individuals.Objetivo: La investigación se centra en abordar la importancia de la HAS como potencial factor de riesgo en pacientes afectados por COVID-19. Métodos: La metodología adoptada en el presente estudio se basó en una revisión sistemática de la literatura, en su esfera cualitativa, resultado de estudios basados ​​en 10 artículos científicos, una vez enumerados para la formación de este estudio. Resultados: El total de personas con HAS en la presente muestra es de 5.234 con una edad media de 60 años. Los fármacos más utilizados fueron los Antagonistas de los Canales de Calcio, los Beta Bloqueadores de los Receptores de Angiotensina (ARB), los Inhibidores de la Enzima Convertidora de Angiotensina (IECA) y los Alfa Bloqueadores. En este meandro, los resultados mostraron que el uso de (ACEI) y bloqueadores de los receptores de angiotensina (ARB), en comparación con no-ACEI/ARB, no empeoran el COVID-19. La evidencia actual sugiere que las IRAG deben continuarse en el caso de pacientes infectados con el virus. Algunos estudios han informado que los pacientes con HSA tienen un mayor riesgo de tener una afección más grave si dan positivo para la nueva cepa de coronavirus. Conclusión: La presente investigación concluyó que los pacientes hipertensos con COVID-19 tienen mayor riesgo de empeorar la enfermedad que los pacientes no hipertensos. Estos hallazgos revelan que el empeoramiento del estado de los pacientes hipertensos y con COVID-19 se debe al sistema renina-angiotensina-aldosterona (SRAA), que acaba favoreciendo la unión del virus al organismo de estos individuos.Objetivo: A pesquisa tem como foco abordar a importância da HAS como um potencial fator de risco nos quadros de pacientes acometidos pela COVID-19. Métodos: A metodologia adotada no presente estudo foi baseada em uma revisão bibliográfica sistemática, na sua esfera qualitativa, fruto dos estudos baseados em 10 artigos científicos, uma vez elencados para a formação deste estudo. Resultados: O número total de pessoas com HAS na amostra presente é de 5.234 com faixa etária média de 60 anos. Os fármacos mais utilizados foram Antagonistas dos Canais de Cálcio, Betabloqueadores dos Receptores de Angiotensina (BRA), Inibidores da Enzima Conversora de Angiotensina (IECA) e Alfabloqueadores. Nesse meandro, os resultados demostraram que o uso de (IECA) e os bloqueadores dos receptores de Angiotensina (BRA), comparado aos não IECA/BRA, não agravam a COVID-19. A evidencia atual sugere que os ISRAA devem ser continuados em caso de pacientes contaminados pelo vírus. Alguns estudos relataram que pacientes HAS tem maior risco de apresentar um quadro mais grave em caso de positivo para a nova cepa do coronavírus. Conclusão: A presente pesquisa concluiu que pacientes hipertensos portadores de COVID-19 tem maior risco de agravamento da doença do que os não hipertensos. Tais achados revelam que a piora do quadro de pacientes hipertensos e portadores da COVID-19 se dá pelo sistema renina-angiotensina-aldosterona (SRAA), que acabam favorecendo a ligação do vírus ao organismo desses indivíduos.Research, Society and Development2022-03-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2728210.33448/rsd-v11i4.27282Research, Society and Development; Vol. 11 No. 4; e33711427282Research, Society and Development; Vol. 11 Núm. 4; e33711427282Research, Society and Development; v. 11 n. 4; e337114272822525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/27282/23964Copyright (c) 2022 Jemilly Ferreira de Sousa; Edilson Soares Lima; Mônica Aparecida Miranda Carvalho; Pedro Henrique Coêlho Soares; Raquel Santos Muniz; Renandro de Carvalho Reishttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSousa, Jemilly Ferreira deLima, Edilson SoaresCarvalho, Mônica Aparecida MirandaSoares, Pedro Henrique Coêlho Muniz, Raquel SantosReis, Renandro de Carvalho2022-03-27T17:17:09Zoai:ojs.pkp.sfu.ca:article/27282Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:45:04.634189Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review
Los efectos del COVID-19 en pacientes con hipertensión arterial sistémica: una revisión sistemática
Os efeitos da COVID-19 em pacientes com hipertensão arterial sistêmica: uma revisão sistemática
title The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review
spellingShingle The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review
Sousa, Jemilly Ferreira de
Covid-19
Systemic Arterial Hypertension
Hypertensive.
Covid-19
Hipertensión Arterial Sistémica
Hipertensos.
Covid-19
Hipertensão Arterial Sistêmica
Hipertensos.
title_short The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review
title_full The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review
title_fullStr The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review
title_full_unstemmed The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review
title_sort The effects of COVID-19 on patients with systemic arterial hypertension: a systematic review
author Sousa, Jemilly Ferreira de
author_facet Sousa, Jemilly Ferreira de
Lima, Edilson Soares
Carvalho, Mônica Aparecida Miranda
Soares, Pedro Henrique Coêlho
Muniz, Raquel Santos
Reis, Renandro de Carvalho
author_role author
author2 Lima, Edilson Soares
Carvalho, Mônica Aparecida Miranda
Soares, Pedro Henrique Coêlho
Muniz, Raquel Santos
Reis, Renandro de Carvalho
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Sousa, Jemilly Ferreira de
Lima, Edilson Soares
Carvalho, Mônica Aparecida Miranda
Soares, Pedro Henrique Coêlho
Muniz, Raquel Santos
Reis, Renandro de Carvalho
dc.subject.por.fl_str_mv Covid-19
Systemic Arterial Hypertension
Hypertensive.
Covid-19
Hipertensión Arterial Sistémica
Hipertensos.
Covid-19
Hipertensão Arterial Sistêmica
Hipertensos.
topic Covid-19
Systemic Arterial Hypertension
Hypertensive.
Covid-19
Hipertensión Arterial Sistémica
Hipertensos.
Covid-19
Hipertensão Arterial Sistêmica
Hipertensos.
description Objective: The research focuses on addressing the importance of SAH as a potential risk factor in patients affected by COVID-19. Methods: The methodology adopted in the present study was based on a systematic literature review, in its qualitative sphere, the result of studies based on 10 scientific articles, once listed for the formation of this study. Results: The total number of people with SAH in the present sample is 5,234 with a mean age of 60 years. The most used drugs were Calcium Channel Antagonists, Angiotensin Receptor Beta Blockers (ARB), Angiotensin Converting Enzyme Inhibitors (ACEI) and Alpha Blockers. In this meander, the results showed that the use of (ACEI) and Angiotensin Receptor Blockers (ARB), compared to non-ACEI/ARB, do not worsen COVID-19. Current evidence suggests that SARIs should be continued in the case of patients infected with the virus. Some studies have reported that SAH patients are at greater risk of having a more serious condition if they test positive for the new strain of coronavirus. Conclusion: The present research concluded that hypertensive patients with COVID-19 are at greater risk of worsening the disease than non-hypertensive patients. These findings reveal that the worsening of the condition of hypertensive patients and those with COVID-19 is due to the renin-angiotensin-aldosterone system (RAAS), which ends up favoring the binding of the virus to the body of these individuals.
publishDate 2022
dc.date.none.fl_str_mv 2022-03-20
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/27282
10.33448/rsd-v11i4.27282
url https://rsdjournal.org/index.php/rsd/article/view/27282
identifier_str_mv 10.33448/rsd-v11i4.27282
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/27282/23964
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 4; e33711427282
Research, Society and Development; Vol. 11 Núm. 4; e33711427282
Research, Society and Development; v. 11 n. 4; e33711427282
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052707461136384